No Data
Amoy Diagnostics (300685.SZ): has obtained the invention patent certificate.
Gelonghui, on December 13th, announced that Amoy Diagnostics (300685.SZ) recently received an invention patent certificate issued by the Japan Patent Office. The patent is titled "Probe primer set for detecting gene mutations in myeloid leukemia based on high-throughput sequencing and its application," with patent number 7591097, classified as an invention. The patent rights are valid for twenty years from the date of application, and the patent holder is the company.
PD-L1 Tests Market Research Report 2024, Featuring F. Hoffmann-La Roche, Agilent Technologies, Amoy Diagnostics, BioGenex Laboratories - Segments, Share, Regulatory, Reimbursement and Forecast to 2036 - ResearchAndMarkets.com
Estimating The Intrinsic Value Of Amoy Diagnostics Co., Ltd. (SZSE:300685)
amoy diagnostics (300685.SZ): Cumulatively repurchased 1.17% of shares.
Gelonghui November 4th丨Amoy Diagnostics (300685.SZ) announced that as of October 31, 2024, the company implemented the repurchase of 4,666,240 shares through a special securities account for centralized competitive trading, accounting for 1.17% of the company's current total share capital. The highest fill price for repurchased shares was 21.91 yuan/share, the lowest fill price was 17.20 yuan/share, and the total amount paid was 85,835,044.00 yuan (excluding transaction fees). This repurchase complies with the company's established share repurchase program and relevant legal requirements.
Amoy Diagnostics Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
Despite Delivering Investors Losses of 43% Over the Past 3 Years, Amoy Diagnostics (SZSE:300685) Has Been Growing Its Earnings
Are Strong Financial Prospects The Force That Is Driving The Momentum In Amoy Diagnostics Co., Ltd.'s SZSE:300685) Stock?
